MedTrace Logo

A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer

NCT06643910 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-10-16

No results posted yet for this study

Summary

This study is an exploratory clinical trial initiated by an open, single arm researcher to evaluate the safety, tolerability, and preliminary efficacy of BST08 in the treatment of advanced non-small cell lung cancer in subjects. This study plans to set up two experimental groups: monotherapy group A: 9x10 \^ 10 BST08 (3 cases) and combination therapy group B: 9x10 \^ 10 BST08+Pabolizhu 200mg Q3W (6 cases).

Conditions

Interventions

BIOLOGICAL

Single drug group A

9x10\^10 BST08 cells, Intravenous infusion，3 subject is planned to be enrolled

BIOLOGICAL

Combined treatment group B

9x10\^10 BST08 cells+ Pembrolizumab Injection，200mg，Q3W, Intravenous infusion，6subject is planned to be enrolled

Sponsors & Collaborators

  • South China Hospital of Shenzhen University

    collaborator UNKNOWN

  • BioSyngen Pte Ltd

    lead INDUSTRY

Principal Investigators

  • Yuqing Li, PhD · South China Hospital of Shenzhen University

  • Mingyong Han, PhD · South China Hospital of Shenzhen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-24
Primary Completion
2026-08-31
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643910 on ClinicalTrials.gov